Sponsor

UCB Biopharma SRL

Clinical research sponsor

How to interpret these research links

Connected source records

The exact organization name UCB Biopharma SRL appears in 13 distinct published trial records. The links retain registry-reported sponsor and collaborator roles; differently spelled legal entities are not automatically merged. Recruiting status describes the current published registry snapshot, not an independently verified availability guarantee.

Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.

Published trials13
Recruiting shown3
Roles2
SourceClinicalTrials.gov
Advertisement

Clinical trials

13 shown
A Study of 24 to 52 Weeks Treatment to Evaluate The Efficacy And Safety of Galvokimig in Study Participants With Moderate-to-Severe Chronic Obstructive Pulmonary Disease (COPD) With Chronic BronchitisNCT07725939 · lead sponsor · 2026-07-27
RECRUITING
A Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of UCB0022 in Study Participants With Advanced Parkinson's DiseaseNCT06055985 · lead sponsor · 2023-11-17
COMPLETED
An Extension Study to Evaluate the Long-Term Efficacy, Safety and Tolerability of Minzasolmin (UCB0599) in Study Participants With Parkinson's DiseaseNCT05543252 · lead sponsor · 2022-08-29
TERMINATED
A Study to Test the Efficacy, Safety, and Tolerability of Bepranemab (UCB0107) in Patients With Mild Cognitive Impairment or Mild Alzheimer's Disease (AD)NCT04867616 · lead sponsor · 2021-06-09
COMPLETED
A Study to Test the Safety, Tolerability, and Blood Levels of UCB0022 in Healthy Participants and Participants With Parkinson's DiseaseNCT04867642 · lead sponsor · 2021-04-29
COMPLETED
A Study to Assess the Pulmonary Safety of Staccato Alprazolam in Healthy Study Participants and in Study Participants With Mild AsthmaNCT04802746 · lead sponsor · 2021-03-09
COMPLETED
A Study to Assess the Pharmacokinetics of Certolizumab Pegol in Adults With Active Rheumatoid ArthritisNCT04740814 · lead sponsor · 2021-02-11
COMPLETED
A 18-month Study to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of Oral UCB0599 in Study Participants With Early-stage Parkinson's DiseaseNCT04658186 · lead sponsor · 2020-12-30
COMPLETED
A Safety and Pharmacokinetics Study of UCB7853 in Healthy Study Participants and Study Participants With Parkinson's Disease (PD)NCT04651153 · lead sponsor · 2020-12-14
COMPLETED
A Study in Pregnant Women With Chronic Inflammatory Diseases Treated With Cimzia (Certolizumab Pegol)NCT04163016 · lead sponsor · 2020-06-19
COMPLETED
Named Patient Program With Certolizumab Pegol in Adults Suffering From Rheumatoid Aarthritis (RA)NCT03559686 · lead sponsor
NO_LONGER_AVAILABLE
A Phase I/II Trial of UCB4594 in Participants With Advanced CancerNCT06380816 · collaborator · 2024-07-09
RECRUITING
Prodromal Alpha-Synuclein Screening in Parkinson's Disease StudyNCT04724941 · collaborator · 2021-06-01
RECRUITING

Drugs studied in this sponsor's trials

3 mapped RxNorm concepts

These drug records are connected through ClinicalTrials.gov studies listing UCB Biopharma SRL as a sponsor, collaborator or responsible party. Each count is the number of distinct trials containing the mapped drug intervention. This does not establish that the organization manufactures, owns, sells or developed the drug.

Most studied mapped drug conceptsDistinct linked trials per RxNorm concept; one trial may study several drugs.
certolizumab pegol2
alprazolam1
placebo1

Sponsor roles

lead sponsor11
collaborator2
Advertisement

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.